That is one way to look at it. I personally think it's unlikely. Would Eisai - big pharma with a multi-billion dollar market cap - try and pressure a microcap vendor by threatening to withhold work over $15m over 7 years? Why would they give back anything to Cogstate if this was the case?
This amendment is likely to have been initiated by Cogstate because they think more than $15m can be extracted from the IP by moving Eisai to a non-exclusive agreement.
Eisai always wanted Cognigram as a lead-gen tool for their own approved AZ drugs. Looking at this from afar when a number of AZ treatments are made available, it's much better not to have a digital assessment tied to specific drug company or a specific treatment. There will be less room for conflict of interest and less motivation for big pharma companies to introduce their own individual exclusive digital assessments.
- Forums
- ASX - By Stock
- CGS
- Ann: Eisai and Cogstate Amend Global License Agreement
Ann: Eisai and Cogstate Amend Global License Agreement, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGS (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
0.015(1.35%) |
Mkt cap ! $192.9M |
Open | High | Low | Value | Volume |
$1.12 | $1.13 | $1.07 | $165.2K | 152.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 7938 | $1.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 25369 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 7938 | 1.075 |
2 | 9343 | 1.070 |
1 | 5000 | 1.050 |
2 | 2800 | 1.000 |
1 | 1400 | 0.900 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 25369 | 1 |
1.140 | 5000 | 1 |
1.200 | 12900 | 1 |
1.220 | 1160 | 1 |
1.230 | 23012 | 1 |
Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
Featured News
CGS (ASX) Chart |